Patients with oligometastatic lung cancer may live longer with surgery, but experts stress the need for multidisciplinary ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...

Prespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...

Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

Results from the Phase Ib/II CARTITUDE-1 trial demonstrated that a single infusion of Carvykti delivered durable, ...

AMPLITUDE is the “first trial to show efficacy for the combination of inhibition of PARP and the androgen receptor pathway in metastatic, castration-sensitive prostate cancer with alteration of genes ...

ASCO Data Shows New Therapy Keeps Myeloma Patients in Remission for 5+ Years. Here's what you need to know about the ...

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.